Consensus $11.87. Narrows FY25 revenue view $16.15B-$16.25B from $16.1B-$16.3B, consensus $16.17B. The company said, “The company is reaffirming the midpoint of its full-year 2025 guidance and narrowing the ranges as follows: revenue expected to be between $16,150 million and $16,250 million, Adjusted EBITDA expected to be between $3,775 million and $3,800 million, and Adjusted Diluted Earnings per Share expected to be between $11.85 and $11.95. This revenue guidance includes approximately $100 million of COVID-related revenue step-down, entirely in R&DS, approximately 100 basis points of tailwind from foreign exchange, and approximately 150 basis points of contribution from acquisitions. All financial guidance assumes foreign currency exchange rates as of October 27, 2025, remain in effect for the forecast period.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV:
- Iqvia reports Q3 adjusted EPS $3.00, consensus $2.98
- Cenobamate’s Real-World Impact: A New Hope for Focal Epilepsy?
- IQVIA’s Latest Clinical Study Update: A Game Changer in Cardiovascular Treatment?
- IQVIA’s Innovative Approach: The Carry Life UF System Study Update
- IQVIA’s Latest Clinical Study on NOC-110: A Potential Game-Changer for Chronic Cough